Form 4: Codexis CSO Lutz Sells Shares, Receives New Stock Options

Codexis Chief Scientific Officer Stefan Lutz reported a sale of common stock to cover tax obligations and the grant of 316,100 new stock options.

Summary

• Chief Scientific Officer Stefan Lutz sold 5,862 shares of Codexis common stock on February 24, 2026, at a price of $1.1329 per share.
• The sale was conducted solely to satisfy tax and government withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Lutz beneficially owns 130,421 shares of common stock, which includes 23,299 RSUs.
• Lutz was granted 316,100 stock options on February 23, 2026, with an exercise price of $1.07 per share.
• These options will vest 25% on the first anniversary of the grant date, and 1/48th of the original number of shares monthly thereafter, contingent on continued employment.
• The stock options expire on February 23, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. While there was a small sale of shares, it was for tax purposes. The significant grant of new stock options to the Chief Scientific Officer indicates continued executive incentive and commitment to the company's long-term success.

Positives

• Grant of 316,100 stock options to the Chief Scientific Officer, indicating continued incentive and alignment with company performance.
• The stock options have a 10-year expiration date (February 23, 2036), providing a long-term incentive horizon.

Negatives

• Sale of 5,862 shares of common stock by a key executive, even if for tax purposes, reduces direct ownership.

Future Outlook

The stock options granted to Stefan Lutz include a vesting schedule over several years, indicating a long-term incentive structure tied to his continued employment and the company's future performance.

Industry Context

StockSavvy.ai notes that the grant of new stock options to a Chief Scientific Officer is a common practice in the biotechnology and specialty chemicals sectors, aiming to align executive incentives with long-term shareholder value creation. The sale of shares to cover tax obligations upon RSU vesting is also a standard, non-discretionary event for executives receiving equity compensation.

Comparison to Industry Standards

• The grant of 316,100 stock options to a Chief Scientific Officer is a significant equity award, comparable to grants seen in similar-sized biotech or enzyme engineering companies for key scientific leadership roles. For instance, executives at companies like Zymergen (before its acquisition) or Ginkgo Bioworks often receive substantial equity packages to incentivize innovation and retention.
• The vesting schedule (25% after one year, then monthly over the next three years) is a standard four-year vesting period, common across the tech and biotech industries to ensure long-term commitment.
• The exercise price of $1.07, close to the market price at the time of grant, is typical for incentive stock options.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the Chief Scientific Officer's interests with long-term shareholder value. The small sale for tax purposes is a routine event and unlikely to have a significant impact.
• Employees: The equity compensation structure for a key executive may set a precedent or reflect the company's broader approach to incentivizing its talent.

Next Steps

• The granted stock options will vest 25% on the first anniversary of the grant date (February 23, 2027).
• Following the initial vesting, 1/48th of the original number of shares subject to the option will vest on each monthly anniversary thereafter, subject to continued employment.
• The stock options will expire on February 23, 2036.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation. The sale of shares was for tax purposes, and the grant of new stock options is a positive for executive alignment. However, these transactions alone do not provide sufficient new information to warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Codexis, CDXS, Stefan Lutz, Chief Scientific Officer, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Tax Withholding